Fluorouracil Hikma 50 mg/ml Injektionslösung

DRUG3 trials

Sponsors

Leap Therapeutics Inc., Janssen - Cilag International, Institut De Recherches Internationales Servier IRIS

Conditions

Advanced or Metastatic Colorectal CancerBRAF and Other Selected RAS/MAPK MutationsColorectal CancerMalignancies with Documented KRAS

Phase 1

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer

RecruitingCTIS2023-506517-22-00

Janssen - Cilag InternationalAdvanced or Metastatic Colorectal Cancer

Start: 2022-08-31Target: 37Updated: 2025-12-12

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Not yet recruitingCTIS2025-523474-16-00

Institut De Recherches Internationales Servier IRISBRAF and Other Selected RAS/MAPK Mutations, Malignancies with Documented KRAS

Target: 75Updated: 2026-04-22

Phase 2

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

CompletedCTIS2022-501465-40-00

Leap Therapeutics Inc.Colorectal Cancer

Start: 2023-12-22End: 2025-07-02Target: 25Updated: 2025-06-12